Reuters logo
UPDATE 1-Ultragenyx seizure drug fails mid-stage study
2017年3月22日 / 晚上9点08分 / 8 个月前

UPDATE 1-Ultragenyx seizure drug fails mid-stage study

(Adds details, shares)

March 22 (Reuters) - Ultragenyx Pharmaceutical Inc said its drug to treat patients with seizures did not meet the main goal in a mid-stage study, sending its shares down 6.2 percent in after-market trading on Wednesday.

The company said the study did not show statistical significance in reducing the frequency of seizures among patients treated with the drug compared to a placebo, during a eight week treatment period.

Ultragenyx’s experimental treatment for mucopolysaccharidosis — a rare genetic, metabolic disorder when the body is unable to breakdown GAGs, a kind of complex carbohydrate — is in its late stage.

The company’s other rare and ultra-rare disease treatments are in its mid-stages. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Shounak Dasgupta)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below